2-methoxyestradiol-induced apoptosis in cancer cells
US5958892A · kind A · utility
18Cited by
0References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 30, 1996 |
| Grant date | Sep 28, 1999 |
| Priority date | — |
| Expiry date | Jul 30, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention details methods for the treatment of cancer. In particular, it concerns the induction of apoptosis of cancer cells following treatment with methoxyestradiol. 2-methoxyestradiol (2-MeOE.sub.2) increase wild-type p53 levels in a human non-small lung cancer cell lines associated with accumulation of cyclin dependent kinase inhibitor p21 WAF1/CIP1. Significant apoptotic cell death occurred after the drug treatment. Thus, 2-MeOE.sub.2 facilitates induction of p53-mediated apoptosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.